California-based molecular diagnostics company Cepheid (CPHD) has received the U.S. Food & Drug Administration (:FDA) clearance for the sale of its on-demand molecular test – Xpert Flu/RSV XC – in the ...
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A respiratory test maker is ...
The agreement significantly expands a longtime partnership between Cepheid - a Danaher operating company - and the Global Fund to improve access to testing where it matters most. Both Cepheid and the ...
Cepheid said it will partner with MedImmune and a European public/private partnership that promotes anti-infective drug development to develop rapid diagnostic tests in respiratory secretions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results